A team of researchers at the University of Pennsylvania took a new approach, using mRNA technology to design a multipronged vaccine that targets several proteins that underlie C. difficile’s ...

Moderna (MRNA) reachead $53.80 at the closing of the latest trading day, reflecting a -0.55% change compared to its last close. We recently compiled a list of the 10 Best QQQ Stocks to Buy ...

mRNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...

"We sought to explore if these attributes could be exploited to engineer highly stable and minimally toxic LNPs for mRNA delivery," the researchers report in the paper. By carefully testing ...

But this is the first phase-IIb randomised clinical trial to test the investigational mRNA vaccine in patients. Could Covid vaccine technology crack cancer? Patients taking Keytruda for advanced ...

How does a COVID-19 mRNA vaccine work? COVID vaccines are now available. Some of the COVID-19 vaccines are mRNA vaccines, but what does this mean? mRNA vaccines are different from traditional ...

This means adults have a choice in which COVID vaccine they receive: an mRNA vaccine by Moderna or Pfizer, or Novavax, a protein-based vaccine that targets the virus in a more "traditional" way.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine ...